Vir Biotechnology, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Vir Biotechnology, Inc. on May 29, 2024. As of the record date of April 1, 2024, 135,843,977 shares of common stock were outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Three proposals were submitted to a vote of security holders:
- Proposal 1: Election of Directors - Stockholders elected four Class II Directors to serve until the 2027 Annual Meeting.
- Marianne De Backer: 105,598,679 votes for; 1,121,748 withheld.
- Norbert Bischofberger: 80,025,502 votes for; 26,694,925 withheld.
- Ramy Farid: 106,416,937 votes for; 303,490 withheld.
- Robert Nelsen: 67,895,334 votes for; 38,825,093 withheld.
- Proposal 2: Advisory Vote on Executive Compensation - Approved.
- Votes For: 83,922,789
- Votes Against: 22,639,307
- Abstentions: 158,331
- Proposal 3: Ratification of Independent Auditor - Ratified Ernst & Young LLP for the fiscal year ending December 31, 2024.
- Votes For: 118,125,237
- Votes Against: 679,046
- Abstentions: 168,971
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the tenure of the newly elected Class II Directors (through 2027).
- Note the significant number of votes withheld for directors Norbert Bischofberger and Robert Nelsen compared to other nominees.
- Confirm the approval of executive compensation despite approximately 21% of votes cast being against the proposal.
- Review the upcoming fiscal year 2024 financial reports for the audited financial data not included in this 8-K.